Does BLEOMYCIN Cause Second primary malignancy? 230 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 230 reports of Second primary malignancy have been filed in association with BLEOMYCIN (Bleomycin). This represents 3.3% of all adverse event reports for BLEOMYCIN.
230
Reports of Second primary malignancy with BLEOMYCIN
3.3%
of all BLEOMYCIN reports
104
Deaths
38
Hospitalizations
How Dangerous Is Second primary malignancy From BLEOMYCIN?
Of the 230 reports, 104 (45.2%) resulted in death, 38 (16.5%) required hospitalization, and 16 (7.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BLEOMYCIN. However, 230 reports have been filed with the FAERS database.
What Other Side Effects Does BLEOMYCIN Cause?
Off label use (656)
Febrile neutropenia (632)
Neutropenia (433)
Drug ineffective (395)
Pyrexia (291)
Product use in unapproved indication (280)
Pulmonary toxicity (263)
Thrombocytopenia (260)
Nausea (255)
Anaemia (252)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which BLEOMYCIN Alternatives Have Lower Second primary malignancy Risk?
BLEOMYCIN vs BLINATUMOMAB
BLEOMYCIN vs BLONANSERIN
BLEOMYCIN vs --BLOOD-COAGULATION FACTOR VIII FUSION PROTEIN WITH IMMUNOGLOBULIN G1 , ,-BIS WITH IMMUNOGLOBULIN G1
BLEOMYCIN vs BOCEPREVIR
BLEOMYCIN vs BOCOCIZUMAB